Literature DB >> 16879803

Epigenetic silencing of MHC2TA transcription in cancer.

Tjadine M Holling1, Marja C J A van Eggermond, Martine J Jager, Peter J van den Elsen.   

Abstract

Lack of expression of major histocompatibility complex (MHC) molecules of both classes is frequently noted on tumour cells . It is thought that in this way tumour cells escape immunosurveillance. The genes encoding both classes of MHC molecules are localized on the distal part of chromosome 6 (6p21.3). The class II transactivator (CIITA), encoded by the MHC2TA gene, is essential for transcriptional activation of all MHC-II genes, while it has a helper function in the transcriptional regulation of MHC-I genes (with the exception of human leukocyte antigen (HLA)-G) and of the gene encoding beta2-microglobulin (beta2m) . Here we discuss our current knowledge on the expression characteristics of MHC2TA and argue for an important role of epigenetic factors and mechanisms in the transcriptional silencing of MHC2TA in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16879803     DOI: 10.1016/j.bcp.2006.06.034

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  13 in total

1.  Phosphorylation and ubiquitination of degron proximal residues are essential for class II transactivator (CIITA) transactivation and major histocompatibility class II expression.

Authors:  Kavita Purnanda Bhat; Agnieszka Dorota Truax; Susanna Fletcher Greer
Journal:  J Biol Chem       Date:  2010-06-10       Impact factor: 5.157

2.  CIITA is silenced by epigenetic mechanisms that prevent the recruitment of transactivating factors in rhabdomyosarcoma cells.

Authors:  Priya Londhe; Bo Zhu; Jinu Abraham; Charles Keller; Judith Davie
Journal:  Int J Cancer       Date:  2012-01-11       Impact factor: 7.396

3.  HLA-DRB1 genes and the expression dynamics of HLA CIITA determine the susceptibility to T2DM.

Authors:  Rathika Chinniah; Vandit Sevak; Sasiharan Pandi; Padma Malini Ravi; Murali Vijayan; Arun Kannan; Balakrishnan Karuppiah
Journal:  Immunogenetics       Date:  2021-03-22       Impact factor: 2.846

4.  Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes.

Authors:  Sara Michel; Michael Linnebacher; Joshua Alcaniz; Maike Voss; Rudolf Wagner; Wolfgang Dippold; Christina Becker; Magnus von Knebel Doeberitz; Soldano Ferrone; Matthias Kloor
Journal:  Int J Cancer       Date:  2010-08-15       Impact factor: 7.396

5.  Distinct MHC gene expression patterns during progression of melanoma.

Authors:  Yan Degenhardt; Jia Huang; Joel Greshock; Galene Horiates; Katherine Nathanson; Xiaolu Yang; Meenhard Herlyn; Barbara Weber
Journal:  Genes Chromosomes Cancer       Date:  2010-02       Impact factor: 5.006

6.  Transcriptional coactivator CIITA, a functional homolog of TAF1, has kinase activity.

Authors:  Katherine C Soe; Ballachanda N Devaiah; Dinah S Singer
Journal:  Biochim Biophys Acta       Date:  2013-09-13

7.  Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.

Authors:  Kelly A Cycon; Kathleen Mulvaney; Lisa M Rimsza; Daniel Persky; Shawn P Murphy
Journal:  Immunology       Date:  2013-10       Impact factor: 7.397

8.  Dysregulated recruitment of the histone methyltransferase EZH2 to the class II transactivator (CIITA) promoter IV in breast cancer cells.

Authors:  Agnieszka D Truax; Meghna Thakkar; Susanna F Greer
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240

9.  Expression regulation of major histocompatibility complex class I and class II encoding genes.

Authors:  Peter J van den Elsen
Journal:  Front Immunol       Date:  2011-10-04       Impact factor: 7.561

10.  Identification of CIITA regulated genetic module dedicated for antigen presentation.

Authors:  Michal Krawczyk; Queralt Seguín-Estévez; Elisa Leimgruber; Peter Sperisen; Christoph Schmid; Philipp Bucher; Walter Reith
Journal:  PLoS Genet       Date:  2008-04-25       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.